Annual EBITDA
-$61.94 M
-$3.94 M-6.79%
December 31, 2023
Summary
- As of February 26, 2025, SLN annual EBITDA is -$61.94 million, with the most recent change of -$3.94 million (-6.79%) on December 31, 2023.
- During the last 3 years, SLN annual EBITDA has fallen by -$16.34 million (-35.83%).
- SLN annual EBITDA is now -4110.45% below its all-time high of -$1.47 million, reached on December 31, 1995.
Performance
SLN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$27.90 M
-$6.28 M-29.02%
September 30, 2024
Summary
- As of February 26, 2025, SLN quarterly EBITDA is -$27.90 million, with the most recent change of -$6.28 million (-29.02%) on September 30, 2024.
- Over the past year, SLN quarterly EBITDA has dropped by -$9.38 million (-50.68%).
- SLN quarterly EBITDA is now -580.58% below its all-time high of -$4.10 million, reached on March 31, 2024.
Performance
SLN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$72.14 M
-$14.57 M-25.31%
September 30, 2024
Summary
- As of February 26, 2025, SLN TTM EBITDA is -$72.14 million, with the most recent change of -$14.57 million (-25.31%) on September 30, 2024.
- Over the past year, SLN TTM EBITDA has dropped by -$12.33 million (-20.61%).
- SLN TTM EBITDA is now -498.65% below its all-time high of -$12.05 million, reached on September 30, 2020.
Performance
SLN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SLN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.8% | -50.7% | -20.6% |
| 3 y3 years | -35.8% | -59.3% | -24.9% |
| 5 y5 years | -130.7% | -59.3% | -24.9% |
SLN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -6.8% | +0.9% | -580.6% | at low | -45.1% | at low |
| 5 y | 5-year | -117.0% | +0.9% | -580.6% | at low | -498.6% | at low |
| alltime | all time | -4110.4% | +0.9% | -580.6% | at low | -498.6% | at low |
Silence Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$27.90 M(+29.0%) | -$72.14 M(+25.3%) |
| Jun 2024 | - | -$21.62 M(+427.5%) | -$57.57 M(+15.8%) |
| Mar 2024 | - | -$4.10 M(-77.9%) | -$49.71 M(-16.9%) |
| Dec 2023 | -$61.94 M(+6.8%) | -$18.52 M(+38.9%) | -$59.81 M(+1.7%) |
| Sep 2023 | - | -$13.33 M(-3.2%) | -$58.81 M(+4.5%) |
| Jun 2023 | - | -$13.77 M(-3.0%) | -$56.28 M(-5.0%) |
| Mar 2023 | - | -$14.20 M(-19.0%) | -$59.24 M(+2.6%) |
| Dec 2022 | -$58.00 M(-7.2%) | -$17.52 M(+62.2%) | -$57.74 M(+4.3%) |
| Sep 2022 | - | -$10.80 M(-35.4%) | -$55.37 M(-9.1%) |
| Jun 2022 | - | -$16.73 M(+31.8%) | -$60.95 M(-1.4%) |
| Mar 2022 | - | -$12.69 M(-16.2%) | -$61.81 M(-0.0%) |
| Dec 2021 | -$62.49 M(+37.0%) | -$15.15 M(-7.5%) | -$61.82 M(-3.3%) |
| Sep 2021 | - | -$16.38 M(-6.9%) | -$63.94 M(+7.3%) |
| Jun 2021 | - | -$17.59 M(+38.5%) | -$59.61 M(+41.9%) |
| Mar 2021 | - | -$12.70 M(-26.5%) | -$42.02 M(+43.3%) |
| Dec 2020 | -$45.60 M(+59.8%) | -$17.27 M(+43.3%) | -$29.32 M(+143.3%) |
| Sep 2020 | - | -$12.05 M | -$12.05 M |
| Dec 2019 | -$28.54 M(+6.3%) | - | - |
| Dec 2018 | -$26.85 M(+525.1%) | - | - |
| Dec 2017 | -$4.30 M(-72.7%) | - | - |
| Dec 2016 | -$15.71 M(+7.2%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | -$14.65 M(-24.6%) | - | - |
| Dec 2014 | -$19.44 M(+41.6%) | - | - |
| Dec 2013 | -$13.73 M(+63.3%) | - | - |
| Dec 2012 | -$8.41 M(-3.2%) | - | - |
| Dec 2011 | -$8.69 M(-33.0%) | - | - |
| Dec 2010 | -$12.96 M(+34.5%) | - | - |
| Dec 2009 | -$9.64 M(-30.0%) | - | - |
| Dec 2008 | -$13.76 M(+29.3%) | - | - |
| Dec 2007 | -$10.64 M(+60.9%) | - | - |
| Dec 2006 | -$6.61 M(+6.3%) | - | - |
| Dec 2005 | -$6.22 M(+6.1%) | - | - |
| Dec 2004 | -$5.86 M(+36.3%) | - | - |
| Dec 2003 | -$4.30 M(+46.8%) | - | - |
| Dec 2002 | -$2.93 M(-31.9%) | - | - |
| Dec 2001 | -$4.30 M(+4.8%) | - | - |
| Dec 2000 | -$4.10 M(+16.6%) | - | - |
| Dec 1999 | -$3.52 M(+13.6%) | - | - |
| Dec 1998 | -$3.09 M(-11.1%) | - | - |
| Dec 1997 | -$3.48 M(+84.2%) | - | - |
| Dec 1996 | -$1.89 M(+28.5%) | - | - |
| Dec 1995 | -$1.47 M | - | - |
FAQ
- What is Silence Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Silence Therapeutics?
- What is Silence Therapeutics annual EBITDA year-on-year change?
- What is Silence Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Silence Therapeutics?
- What is Silence Therapeutics quarterly EBITDA year-on-year change?
- What is Silence Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Silence Therapeutics?
- What is Silence Therapeutics TTM EBITDA year-on-year change?
What is Silence Therapeutics annual EBITDA?
The current annual EBITDA of SLN is -$61.94 M
What is the all time high annual EBITDA for Silence Therapeutics?
Silence Therapeutics all-time high annual EBITDA is -$1.47 M
What is Silence Therapeutics annual EBITDA year-on-year change?
Over the past year, SLN annual EBITDA has changed by -$3.94 M (-6.79%)
What is Silence Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SLN is -$27.90 M
What is the all time high quarterly EBITDA for Silence Therapeutics?
Silence Therapeutics all-time high quarterly EBITDA is -$4.10 M
What is Silence Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SLN quarterly EBITDA has changed by -$9.38 M (-50.68%)
What is Silence Therapeutics TTM EBITDA?
The current TTM EBITDA of SLN is -$72.14 M
What is the all time high TTM EBITDA for Silence Therapeutics?
Silence Therapeutics all-time high TTM EBITDA is -$12.05 M
What is Silence Therapeutics TTM EBITDA year-on-year change?
Over the past year, SLN TTM EBITDA has changed by -$12.33 M (-20.61%)